Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma ☆

Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtage...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro
Format:	Artigo
Jezik:	Inglês
Izdano:	Wolters Kluwer Medknow Publications 2023-04-01
Serija:	Hematology/Oncology and Stem Cell Therapy
Teme:	adoptive immunotherapy axicabtagene ciloleucel lymphoma non-hodgkin neoplasm recurrence salvage therapy response predictor
Online dostop:	https://journals.lww.com/10.1016/j.hemonc.2021.09.001
Oznake:	Označite Brez oznak, prvi označite!